[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100657692":3},{"organization":4,"outcomesModule":7,"designInfo":16,"detailedDescription":19,"studyPopulation":20,"armGroups":21,"interventions":11,"overallOfficials":26,"centralContacts":30,"locations":11,"responsibleParty":35,"collaborators":37,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":11,"eligibilityCriteria":46,"healthyVolunteers":43,"sex":47,"minAge":48,"maxAge":11,"enrollmentInfo":49,"targetDuration":11,"studyType":52,"phases":11,"briefSummary":53,"conditions":54,"keywords":59,"overallStatus":65,"whyStopped":11,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":11},{"fullName":5,"class":6},"Umeå University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9,13],{"measure":10,"description":11,"timeFrame":12},"Difference in CGM-derived glycemic variability metrics",null,"14 days CGM recording period",{"measure":14,"description":11,"timeFrame":15},"Difference in gut microbiota composition","Single fecal sample",{"allocation":11,"interventionModel":11,"interventionModelDescription":11,"primaryPurpose":11,"observationalModel":17,"timePerspective":18,"maskingInfo":11},"COHORT","PROSPECTIVE","See Appendix 1 (Research Plan) for a full description of the background, aims, and methods.","The study population consists of consecutive adult patients evaluated or treated for pancreatic or periampullary diseases at the Department of Surgery\u002FCancer Center, Umeå University Hospital, Sweden.",[22,24],{"label":23,"type":11,"description":11,"interventionNames":11},"Patients with pancreatic cancer",{"label":25,"type":11,"description":11,"interventionNames":11},"Patients with cysts or other benign pancreatic disease",[27],{"name":28,"affiliation":5,"role":29},"Oskar Franklin, M.D, PhD","PRINCIPAL_INVESTIGATOR",[31],{"name":28,"role":32,"phone":33,"phoneExt":11,"email":34},"CONTACT","+46 90 7865000","oskar.franklin@umu.se",{"type":36,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[38],{"name":39,"class":40},"Region Västerbotten","OTHER_GOV","100657692","studies-of-blood-glucose-and-the-microbiome-in-tumors-and-cysts-of-the-pancreas-100657692",false,"NCT07843147","Studies of Blood Glucose and the Microbiome in Tumors and Cysts of the Pancreas","Inclusion criteria:\n\n* Adults (≥18 years of age).\n* Undergoing clinical investigation, follow-up, or treatment for a pancreatic or periampullary condition (malignant or benign\u002Fpremalignant, including cystic lesions and pancreatitis).\n* Willing and able to provide written informed consent for participation in at least one component of the study (continuous glucose monitoring and\u002For fecal sample collection).\n\nExclusion criteria:\n\n\\-","ALL","18 Years",{"count":50,"type":51},100,"ESTIMATED","OBSERVATIONAL","This prospective, single-center observational study investigates whether continuous glucose monitoring (CGM, 14 days) and gut microbiota composition (from a fecal sample) reveal patterns specific to pancreatic cancer, aiming to contribute to earlier detection and better assessment of disease severity. Adult patients under investigation, follow-up, or treatment for benign or malignant pancreatic\u002Fperiampullary conditions are invited to participate in either or both parts of the study.",[55,56,57,58],"Pancreatic Neoplasms","Pancreatic Cysts","Hyperglycemia","Prediabetes",[60,61,62,63,64],"continuous glucose monitoring","gut microbiota","pancreatic cancer","biomarker","fecal microbiome","NOT_YET_RECRUITING","2026-09-21",{"date":68,"type":69},"2026-09-25","ACTUAL",{"date":71,"type":51},"2026-10-01",{"date":73,"type":51},"2031-10-01",{"name":5,"class":6}]